IP Group

IP Group is a London-based corporate firm that provides financial, strategic, and commercial expertise to clients internationally. Founded in 2001, the company focuses on creating value through the commercialisation of intellectual property derived from research-intensive institutions. It manages the end-to-end process of identifying viable IP, developing or partnering to build value, and establishing commercial arrangements that translate scientific advances into practical products and businesses. IP Group combines industry insight and financial experience to support science- and technology-based ventures, offering capital as well as strategic guidance to help companies grow and accelerate the impact of research. Its work spans clean technology, life sciences, and other deep technology sectors, with a track record of backing and developing ventures that aim to deliver tangible societal and economic outcomes.

Alan Aubrey

CEO, Executive Director and Member of the Board of Directors

David Baynes

Chief Financial and Operating Officer and Board Member

Jon Edington

Partner, Technology

Ben Murphey

Investment Director

Mark Reilly Ph.D

Managing Partner, Technology

Greg Smith

CEO

Lee Thornton Ph.D

Partner, Technology

Robert Trezona Ph.D

Partner and Head of Cleantech

Ben Murphy

Investment Director, Kiko Ventures

295 past transactions

Lumai

Venture Round in 2025
Lumai specializes in fully optical computing technology, harnessing photonics and machine learning to accelerate artificial intelligence processing. Its innovative processor uses beams of light for rapid data processing, enhancing energy efficiency, and reducing operational expenses.

DiffBlue

Series A in 2024
DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.

Alimetry

Series A in 2024
Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Alesi Surgical

Venture Round in 2024
Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

Microbiotica

Venture Round in 2024
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

MISSION Therapeutics

Venture Round in 2024
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Enterprise Therapeutics

Series B in 2024
Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Oxford Quantum Circuits

Series B in 2023
Oxford Quantum Circuits develops quantum computing technology, aiming to tackle complex challenges such as climate change and drug discovery. Their fully functional quantum computer system enables businesses to explore innovative solutions and address global issues.

Crescendo Biologics

Venture Round in 2023
Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

OxCCU

Series A in 2023
OxCCU develops renewable energy technology to enable a circular economy for fuels, chemicals, and plastics. The technology combines carbon dioxide from the atmosphere with hydrogen from water and renewable electricity to produce fuels, chemicals, and biodegradable plastics and is positioned to deliver the lowest-cost Power to Liquids pathway.

AccelerComm

Series B in 2023
AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) and channel coding solutions for wireless communications. Founded in 2016, the company develops advanced error correction technologies, including Polar and Turbo Decoders, as well as LDPC encoding and decoding chains, which are compliant with 3GPP standards. These technologies are designed to enhance the performance of next-generation wireless communication systems, addressing challenges such as noise, interference, and poor signal quality. By offering innovative solutions that improve the efficiency and reliability of communication networks, AccelerComm aims to support the evolution of mobile technology beyond 3G and 4G standards.

Deep Render

Series A in 2023
Deep Render is a London-based AI startup spun out from Imperial College London's Department of Computing. It develops AI-powered video and image compression technology that leverages deep learning, density estimation, unsupervised learning, and quantum techniques to improve compression efficiency. The company has proprietary, patented technology in media and biological image compression, with state-of-the-art results delivering at least a 50% efficiency gain over previous standards.

Intrinsic Semiconductor Technologies

Venture Round in 2023
Intrinsic Semiconductor Technologies develops silicon oxide–based memristive devices with fully air-stable, CMOS-compatible technology. The company specializes in non-volatile and multilevel memory, and its platforms support hardware acceleration for machine learning and neuromorphic computing. Its memristive materials leverage common processing steps to enable integration in standard devices across advanced process nodes, facilitating operation at higher power, frequency, and temperature ranges. In addition to memory functions, the technology underpins low-power, cost-efficient semiconductors, including gallium nitride materials, suitable for diverse applications in data storage, processing, and next-generation computing architectures.

Quantum Motion

Series B in 2023
Quantum Motion Technologies is developing a universal quantum computer using Silicon-based CMOS processes. Its focus lies in creating scalable arrays of qubits, aiming to develop quantum computing architectures compatible with existing silicon processing methods.

AudioScenic

Series A in 2023
AudioScenic specializes in developing advanced 3D audio technology using small speaker arrays and head tracking. This enables immersive, personalized sound experiences without the need for headphones or multiple speakers, benefiting industries such as gaming, cinema, VR, and automotive.

STORM Therapeutics

Series B in 2022
Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Pulmocide

Series C in 2022
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

DiffBlue

Series A in 2022
DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.

Kale United

Equity Crowdfunding in 2022
Kale United AB, founded in 2018 and headquartered in Stockholm, Sweden, specializes in providing advisory services to plant-based member companies. These services encompass marketing, public relations, sales and distribution, financing, community engagement, accounting, and human resources. The company focuses on supporting vegan startups and aims to foster growth within the plant-based food sector across the Nordic region.

Innervace

Series A in 2022
Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

AMSL Aero

Series B in 2022
AMSL Aero is a developer of electric vertical take-off and landing aircraft. The company designs aircraft intended to provide safe, fast, and environmentally friendly transportation for aeromedical, emergency services, and passenger markets. Its Vertiia model is capable of cruising at about 300 km/h and can travel up to 250 km on a fully electric battery before recharge, aiming to enable a new mode of point-to-point travel with reduced congestion. The company is also developing an autonomous two-seat aircraft designed to improve mobility by enabling high-speed air travel from any location with a suitable landing pad, offering a clean, low-cost alternative to ground transport.

Somalytics

Seed Round in 2022
Somalytics is a Seattle-based company that specializes in the development and commercialization of innovative miniature sensors for applications such as eye tracking, human-machine interfaces, wearables, and industrial safety. Founded in 2021, the company has created the world's first paper-composite capacitive sensor, which is ultra-thin, energy-efficient, and potentially disposable. These carbon nanotube-based sensors enhance sensitivity and aim to replace traditional cameras and sensors in various devices, thereby improving the overall human experience through advanced technology.

Nexeon

Series D in 2022
Nexeon is an international developer and manufacturer of silicon-based anode materials for rechargeable lithium-ion batteries. The company focuses on silicon anodes to increase energy density, enabling lighter, smaller, and more cost-efficient batteries for a range of applications including electric vehicles and consumer electronics, as well as other sectors that require high-performance energy storage. Headquarters are in Oxfordshire, United Kingdom, and the company maintains operations in Japan, with a history dating back to 2006. By replacing traditional graphite anodes, Nexeon's materials aim to enhance battery performance while reducing overall carbon footprint.

Hysata

Series A in 2022
Hysata is focused on advancing hydrogen electrolyzer technology to facilitate the production of green hydrogen, aiming to significantly reduce costs to below $2 per kilogram. This innovative approach is rooted in research from the University of Wollongong's ARC Centre of Excellence for Electromaterials Science, led by Professor Gerry Swiegers. The company’s electrolyzers operate by using electricity to separate water into hydrogen and oxygen, thereby supporting the transition from fossil fuels to sustainable energy sources. Hysata's initiatives are designed to play a crucial role in helping businesses achieve net-zero emissions and accelerate the global move towards environmentally friendly energy solutions.

Oxford Science Enterprises

Venture Round in 2022
Founded in 2015, Oxford Science Enterprises is a venture firm that partners with the University of Oxford to build science-based businesses. It invests primarily in life sciences, AI and software, healthcare, and deep tech sectors, aiming to create companies capable of addressing global challenges such as infectious diseases and nuclear fusion.

Abliva

Post in 2022
Abliva AB is a Swedish pharmaceutical company focused on the research and development of treatments for primary mitochondrial diseases, which are rare and severe conditions caused by dysfunctional mitochondria. The company's pipeline includes KL1333, currently in phase I clinical trials, and NV354, an energy replacement therapy that is preparing for clinical trials. KL1333 is noted for its role as a regulator of NAD+ and NADH, and has received orphan drug designation in both Europe and the United States. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injury. Established in 2000 and headquartered in Lund, Sweden, Abliva has formed collaborations with various institutions, enhancing its research capabilities and clinical development efforts.

MoA Technology

Series B in 2022
MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Ankere Therapeutics

Seed Round in 2022
Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

SLAMcore Limited

Series A in 2022
SLAMcore develops simultaneous localization and mapping (SLAM) solutions for augmented/virtual reality, robotics, and autonomous vehicles. Its technology enables moving robots to localize, navigate, and understand unfamiliar surroundings using visual SLAM, sensor fusion, and event camera SLAM. The company's ETAM 2D and ETAM 3D methods demonstrate real-time, high dynamic range, and resolution intensity for event-based cameras. SLAMcore licenses its algorithms for smart technology like drones and self-driving vehicles.

GripAble

Series A in 2022
GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

Kynos Therapeutics

Seed Round in 2022
Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

Aptatek Biosciences

Seed Round in 2022
Aptatek Biosciences develops portable medical devices for managing inborn diseases. Its flagship product monitors phenylalanine levels in real-time for individuals with Phenylketonuria (PKU), enabling immediate dietary adjustments and improved patient compliance.

Vytal

Series A in 2022
Vytal provides software‑enabled reusable packaging solutions that replace single‑use containers in the food and beverage sector. The company offers a reusable container system coupled with container‑management software to support sustainable takeaway and delivery operations. Its platform operates on a pay‑per‑use model that is cheaper than disposable alternatives, allowing restaurants, supermarkets, caterers, canteens and event organisers to borrow containers for free and return them at designated locations or through delivery services. By enabling convenient borrowing and returning, Vytal maximises both economic and ecological value while reducing packaging waste.

Alimetry

Series A in 2022
Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Helio Display Materials

Series A in 2022
Helio Display Materials is a developer of innovative perovskite-based materials aimed at enhancing display technology. The company focuses on creating materials that enable brighter and more colorful displays while significantly reducing power consumption. By leveraging metal halide perovskites, which can be synthesized using low-temperature processes and earth-abundant precursor materials, Helio aims to produce vibrant and efficient light-emitting technologies for televisions and displays. The company emphasizes collaboration with scientific and industry experts to expedite research and development, ensuring a strong scientific foundation for its intellectual property. Helio's mission is to improve display performance and efficiency, ultimately providing a superior visual experience.

Barocal

Seed Round in 2022
Barocal develops innovative cooling technology designed to meet low-carbon refrigeration needs. Its proprietary materials undergo significant thermal changes under pressure application and removal, enhancing energy efficiency and eliminating greenhouse gas warming impact in commercial food and drink refrigeration.

First Light Fusion

Series C in 2022
First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

Bramble Energy

Series B in 2022
Founded in London in 2016, Bramble Energy specializes in designing and manufacturing high-performance, low-cost fuel cell stacks using printed circuit board (PCB) technology. Their products cater to stationary, portable, and automotive sectors, with customizable options available.

Microbiotica

Series B in 2022
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

DiffBlue

Seed Round in 2022
DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.

Lumai

Seed Round in 2021
Lumai specializes in fully optical computing technology, harnessing photonics and machine learning to accelerate artificial intelligence processing. Its innovative processor uses beams of light for rapid data processing, enhancing energy efficiency, and reducing operational expenses.

CANOPUS Networks

Series A in 2021
Canopus Networks Pty Ltd is an Australian company founded in 2018, specializing in software-defined networking and artificial intelligence technologies. The company focuses on providing solutions for internet service providers to effectively manage and isolate streaming video and gaming traffic, ensuring a consistent user experience during network congestion. Canopus develops a platform that offers encryption-proof network observability, enabling high-speed analysis of network flows. This platform is essential for telecommunications operators who need to monitor application and network performance amidst increasing data rates and encryption challenges. Canopus serves various sectors, including fixed operators, gaming, 5G mobile operators, live video streaming, business applications, security, and government entities.

Navenio

Venture Round in 2021
Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Ieso Digital Health

Series B in 2021
Ieso Digital Health provides online, evidence-based mental health therapy via a digital platform, enabling one-to-one cognitive behavioral therapy delivered by accredited therapists in a virtual, convenient setting. The service covers common mental health conditions such as anxiety, depression, OCD, PTSD, sleep problems, and related issues, and also supports patients with chronic physical health problems, medically unexplained symptoms, and other cognitive concerns. The company uses proprietary technology, including natural language processing and artificial intelligence, to monitor therapist protocol adherence and risk in real time, enabling text-based therapy sessions. It serves health providers including the NHS, private individuals, and employers, expanding access to clinically validated care outside traditional in-person settings.

Ieso Digital Health

Series B in 2021
Ieso Digital Health provides online, evidence-based mental health therapy via a digital platform, enabling one-to-one cognitive behavioral therapy delivered by accredited therapists in a virtual, convenient setting. The service covers common mental health conditions such as anxiety, depression, OCD, PTSD, sleep problems, and related issues, and also supports patients with chronic physical health problems, medically unexplained symptoms, and other cognitive concerns. The company uses proprietary technology, including natural language processing and artificial intelligence, to monitor therapist protocol adherence and risk in real time, enabling text-based therapy sessions. It serves health providers including the NHS, private individuals, and employers, expanding access to clinically validated care outside traditional in-person settings.

Ultraleap

Series D in 2021
Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

Teya

Series C in 2021
Teya is a comprehensive platform serving over 300,000 business owners worldwide. It offers payment processing, loyalty programs, cash advances, and business management tools, empowering small and growing businesses to thrive.

Hinge Health

Series E in 2021
Hinge Health is a digital health company that designs and delivers technology-enabled musculoskeletal care for employees and self-insured employers. The platform combines wearable sensors, computer vision and a clinical team to provide digital physical therapy, guidance on behavior change, and access to orthopedic expertise via a single app. It targets back, neck, shoulder and joint pain and aims to improve access to high-quality care while reducing costs for clients. The solution supports self-management with remote monitoring and personalized programs, enabling physical therapists, health coaches and surgeons to coordinate care. Founded in 2015 and headquartered in San Francisco, it serves businesses and individuals seeking scalable MSK treatment and prevention.

Inosi Therapeutics

Seed Round in 2021
Inosi Therapeutics is a biotechnology company focused on developing innovative therapies to treat fibrosis, a condition characterized by tissue damage and scarring that can result in the loss of organ function. The company is pioneering a therapeutic approach that utilizes IRAP inhibitors, which can be tested independently or in conjunction with existing standard treatments. This unique mechanism of action aims to enhance the treatment of organ damage related to diabetes-induced kidney disease and cardiovascular disease. By addressing the underlying causes of fibrosis, Inosi Therapeutics aims to provide healthcare providers with effective solutions for managing chronic diseases associated with significant tissue damage.

Quantum Dice

Pre Seed Round in 2021
Quantum Dice is a quantum technology company spun out from the University of Oxford that develops quantum random number generators (QRNGs) capable of producing unbiased, true random numbers for cryptographic use. Its QRNG devices are self-certified and rely solely on quantum processes to resist external influences, delivering cryptographically secure randomness for a wide range of commercial applications. The company focuses on enabling stronger encryption and secure communications as industries move toward connected infrastructures.

Monolith AI

Series A in 2021
Monolith AI Limited is a software company based in London, United Kingdom, founded in 2016. The company specializes in developing algorithms that integrate engineering simulations with machine learning techniques to enhance the engineering design process. By leveraging existing simulation and test data, Monolith AI enables engineers to predict the behavior of new products more accurately, thereby optimizing research and development efforts. This approach reduces the need for extensive simulations, tests, and prototypes, allowing companies to accelerate product development and improve overall product quality. Monolith AI was previously known as UQuant Limited until it rebranded in June 2018.

Arkivum

Private Equity Round in 2021
Arkivum is a provider of long-term data preservation and archiving software and services. It offers cloud-based, on-premises and hybrid solutions that store, secure and manage encrypted data for the long term, ensuring data integrity and accessibility in regulated sectors. The company serves higher education, healthcare, life sciences, digital heritage, corporate archives, pharmaceuticals and financial services, and operates through a network of resellers and OEM partners. Arkivum emphasizes vendor-neutral technology with data ownership retained by clients and supports compliance with evolving regulatory requirements through its archiving and data lifecycle tools.

Alesi Surgical

Venture Round in 2021
Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

MOBILion Systems

Series C in 2021
MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Pulmocide

Series C in 2021
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Oxford Nanopore Technologies

Venture Round in 2021
Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Intrinsic Semiconductor Technologies

Seed Round in 2021
Intrinsic Semiconductor Technologies develops silicon oxide–based memristive devices with fully air-stable, CMOS-compatible technology. The company specializes in non-volatile and multilevel memory, and its platforms support hardware acceleration for machine learning and neuromorphic computing. Its memristive materials leverage common processing steps to enable integration in standard devices across advanced process nodes, facilitating operation at higher power, frequency, and temperature ranges. In addition to memory functions, the technology underpins low-power, cost-efficient semiconductors, including gallium nitride materials, suitable for diverse applications in data storage, processing, and next-generation computing architectures.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Oxular

Venture Round in 2021
Oxular is a clinical-stage company developing innovative retinal therapeutics. It focuses on transforming the treatment of retinal diseases by offering tissue-specific drug delivery solutions to address unmet patient needs, such as age-related macular degeneration and diabetic macular edema.

C-Capture Limited

Venture Round in 2021
C-Capture Limited designs and develops solvent systems that capture carbon dioxide from flue gases and other emission sources. The company’s proprietary technology enables reversible, non‑toxic removal of CO2 in post‑combustion capture processes, making power generation and hard‑to‑abate industries more environmentally friendly and cost‑effective. Founded in 2008, the firm is headquartered in Leeds, United Kingdom.

Centessa Pharmaceuticals

Series A in 2021
Centessa Pharmaceuticals is a biopharmaceutical company that focuses on advancing validated drug programs through an asset-centric R&D model. Each program is developed by dedicated subsidiaries, supported by centralized infrastructure and expert management.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Oxa Autonomy

Series B in 2021
Oxa Autonomy develops AI-based software for autonomous vehicle fleets. Their platform enables safe navigation in varied environments, enhancing positioning accuracy and predicting vehicle movements.

8power

Series A in 2020
8power Limited develops wireless sensor technology for industrial plant applications. Its systems monitor machine conditions across thousands of remote assets in sectors like automotive, civil engineering, and utilities.

Econic Technologies

Debt Financing in 2020
Econic Technologies Ltd. is a chemical technology company based in Macclesfield, United Kingdom, specializing in the development of innovative processes to convert carbon dioxide and epoxides into valuable polymers and polyurethanes. Founded in 2011, the company leverages catalyst chemistry to transform waste CO2 into commercially viable products, thereby reducing dependence on fossil fuels and providing environmental benefits. Econic's product offerings include polycarbonates and polycarbonate polyols, which are utilized in various applications such as mattresses, insulation, footwear, packaging, and construction materials. Additionally, the company produces glues and coatings for industrial uses. With patented catalyst technologies and a skilled team of scientists and engineers, Econic Technologies operates from a state-of-the-art facility at Alderley Park, focusing on turning scientific advancements into practical solutions for the plastics industry while addressing environmental challenges.

AudioScenic

Series A in 2020
AudioScenic specializes in developing advanced 3D audio technology using small speaker arrays and head tracking. This enables immersive, personalized sound experiences without the need for headphones or multiple speakers, benefiting industries such as gaming, cinema, VR, and automotive.

Alimetry

Seed Round in 2020
Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Augmented Bionics

Venture Round in 2020
Augmented Bionics is focused on creating a non-surgical alternative to cochlear implants for individuals with severe to profound hearing loss. The company leverages Transcranial Magnetic Stimulation (TMS), a safe and FDA-approved neuromodulation technology, to develop its innovative device. Unlike traditional hearing aids, which are ineffective for this demographic, Augmented Bionics' solution offers the convenience of a wearable device similar to headphones while providing the functionality of a cochlear implant. This approach aims to reduce barriers to access, such as the risks, high costs, and specialist requirements associated with surgical implants. By addressing the needs of the over 70 million people affected by profound hearing loss, Augmented Bionics seeks to transform the treatment landscape and enhance the quality of life for its users.

AccelerComm

Series A in 2020
AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) and channel coding solutions for wireless communications. Founded in 2016, the company develops advanced error correction technologies, including Polar and Turbo Decoders, as well as LDPC encoding and decoding chains, which are compliant with 3GPP standards. These technologies are designed to enhance the performance of next-generation wireless communication systems, addressing challenges such as noise, interference, and poor signal quality. By offering innovative solutions that improve the efficiency and reliability of communication networks, AccelerComm aims to support the evolution of mobile technology beyond 3G and 4G standards.

MOBILion Systems

Series B in 2020
MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Bramble Energy

Series A in 2020
Founded in London in 2016, Bramble Energy specializes in designing and manufacturing high-performance, low-cost fuel cell stacks using printed circuit board (PCB) technology. Their products cater to stationary, portable, and automotive sectors, with customizable options available.

MISSION Therapeutics

Venture Round in 2020
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Oxford Ionics

Seed Round in 2020
Oxford Ionics specializes in advanced quantum computing systems, focusing on trapped-ion technology. This enables scalable, efficient quantum chips produced via standard semiconductor methods, facilitating advancements in quantum computing and enhancing computational capabilities for complex problems.

Navenio

Series A in 2020
Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

IBEX Innovations

Venture Round in 2020
IBEX Innovations develops innovative X-ray detector technology that generates high sensitivity materials information from standard detectors. Its core product, IBEX multi absorption plate (MAP) technology, integrates detectors to provide material insights while maintaining speed and resolution characteristics of underlying sensors. Applications include bone mineral density measurement, electronics inspection, food safety, and security screening.

Quantum Motion

Series A in 2020
Quantum Motion Technologies is developing a universal quantum computer using Silicon-based CMOS processes. Its focus lies in creating scalable arrays of qubits, aiming to develop quantum computing architectures compatible with existing silicon processing methods.

RFC Power

Seed Round in 2020
Founded in London in 2017, RFC Power develops innovative flow battery systems. The company specializes in low-cost hybrid gas-liquid flow batteries, leveraging fuel cell concepts and utilizing non-toxic, abundant materials.

Instrumems

Seed Round in 2020
Instrumems Inc. is a technology company based in Los Altos, California, specializing in the development of innovative nano-wire sensors. Founded in 2016, the company focuses on creating a versatile sensing platform capable of measuring temperature, flow velocity, and humidity. Instrumems' sensors are designed to be faster, more cost-effective, and smaller in size compared to traditional measurement techniques. Their technology is increasingly relevant in various sectors, including aerospace, automotive, and environmental monitoring, facilitating applications such as real-time weather tracking and distributed climate monitoring. The company's multi-sensor solutions leverage high-resolution and high-frequency measurement capabilities, providing clients with industry-leading response times, accuracy, and ultra-low power consumption.

Mixergy

Series A in 2019
Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

MOBILion Systems

Series A in 2019
MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Kira Biotech

Series A in 2019
Founded in 2017, Kira Biotech is an Australian biotechnology company dedicated to developing novel immunomodulatory compounds. Its lead candidate, KB312, is a first-in-class monoclonal antibody targeting activated immune cells to induce immune tolerance and treat immune system disorders such as rheumatoid arthritis and systemic lupus erythematosus.

Inflowmatix

Series B in 2019
Inflowmatix designs and implements electronic systems that provide water flow and system health analytics to water utilities worldwide. Its system optimizes water supply networks by monitoring fluid dynamics, improving leakage management, and extending the life of infrastructure.

CareAlign

Pre Seed Round in 2019
CareAlign is a developer of a real-time data system that enhances the management and coordination of clinical care for clinicians. The company offers an intuitive, patient-centric task management tool that allows healthcare professionals to assign tasks, set deadlines, and categorize them based on urgency. By aggregating data from multiple sources, CareAlign provides a comprehensive and clinically intuitive display of patients' clinical status, facilitating better understanding and decision-making in patient care. This system aims to streamline workflows and improve communication among clinicians, ultimately enhancing the quality of care delivered to patients.

Growave.ag

Seed Round in 2019
Growave is an Agtech startup company offering herbicide free weed management.

WaveOptics

Series C in 2019
WaveOptics, Ltd. is a designer and manufacturer of advanced augmented reality display technology, specializing in diffractive waveguides for wearable devices. Founded in 2014 and headquartered in Abingdon-on-Thames, United Kingdom, the company focuses on providing key optical components for augmented reality applications. WaveOptics employs patented technology that utilizes waveguide holography and photonic crystals to create lightweight, high-performance displays. Their innovative designs feature a high field of view and full RGB color, allowing for an enriched user experience without the bulk typically associated with traditional augmented reality systems. The company has established strategic partnerships with leading firms such as Compal, Wistron, and Plessey to enhance its product offerings and market reach.

SAM Labs

Series A in 2019
SAM Labs Limited is an education technology company based in London, United Kingdom, established in 2014. It specializes in providing educators with resources that enhance teaching and learning experiences, particularly in the areas of coding and computational skills. The company offers a range of products including wireless electronic blocks, such as buttons, sensors, motors, and sliders, which can be connected via an intuitive software application called SAM Space. This platform allows students to visualize and code the blocks, enabling them to create interactive projects and engage in hands-on learning. SAM Labs also supplies curriculum-based lesson plans and in-classroom support to facilitate STEAM education, making coding accessible and fun. Its course kits and electronic products are available for purchase online, helping educators deliver comprehensive and engaging lessons across various subjects.

Exyn

Series A in 2019
Exyn Technologies, Inc. is a Philadelphia-based company that specializes in the development of autonomous aerial robots designed for complex commercial environments. Founded in 2014 as a spin-off from the GRASP Laboratory at the University of Pennsylvania, Exyn leverages over a decade of research to create drone platforms capable of pilot-less operation without reliance on GPS. Its flagship software, exynAI, manages the control and communication of these multi-sensory rotorcraft, enabling them to perform tasks such as underground inspections, inventory management, and construction documentation. The company's innovative approach combines multiple redundant sensors with advanced mapping and obstacle avoidance technologies, resulting in highly robust and differentiated aerial robots that facilitate data acquisition in challenging settings.

Azuri Technologies

Corporate Round in 2019
Azuri Technologies develops, manufactures, and installs solar power products for off-grid emerging markets in Africa and the UK. Its key offerings include AzuriTV (solar-powered television), Indigo (pay-as-you-go solar electricity system using scratch cards), Azuri Quad (solar home system with LED lights, radio/torch, mobile charging), and PayGo (solar home system for rural households). Founded in 2012, the company is headquartered in Cambridge, UK, with distribution networks across multiple African countries.

IBEX Innovations

Venture Round in 2019
IBEX Innovations develops innovative X-ray detector technology that generates high sensitivity materials information from standard detectors. Its core product, IBEX multi absorption plate (MAP) technology, integrates detectors to provide material insights while maintaining speed and resolution characteristics of underlying sensors. Applications include bone mineral density measurement, electronics inspection, food safety, and security screening.

STORM Therapeutics

Series A in 2019
Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Aqdot

Series B in 2019
Founded in 2012, Aqdot specializes in innovative microencapsulation technology. Its patented one-step shrink-wrap approach combines emulsion technology and supramolecular chemistry to create smart microcapsules with customizable properties. This energy-efficient manufacturing process serves various industries, including household care, agrochemicals, and food sectors.

Inivata

Series B in 2019
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

AccelerComm

Seed Round in 2019
AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) and channel coding solutions for wireless communications. Founded in 2016, the company develops advanced error correction technologies, including Polar and Turbo Decoders, as well as LDPC encoding and decoding chains, which are compliant with 3GPP standards. These technologies are designed to enhance the performance of next-generation wireless communication systems, addressing challenges such as noise, interference, and poor signal quality. By offering innovative solutions that improve the efficiency and reliability of communication networks, AccelerComm aims to support the evolution of mobile technology beyond 3G and 4G standards.

C-Capture Limited

Venture Round in 2019
C-Capture Limited designs and develops solvent systems that capture carbon dioxide from flue gases and other emission sources. The company’s proprietary technology enables reversible, non‑toxic removal of CO2 in post‑combustion capture processes, making power generation and hard‑to‑abate industries more environmentally friendly and cost‑effective. Founded in 2008, the firm is headquartered in Leeds, United Kingdom.

Istesso

Venture Round in 2019
Istesso is a biotechnology company focused on drug discovery and development in the field of immunometabolism. Founded in 2017, the company aims to create disease-resolving therapies for chronic autoimmune and inflammatory conditions, including rheumatoid arthritis and multiple sclerosis. Istesso's pipeline consists of both pre-clinical and clinical assets that work by reprogramming metabolic processes to address these complex diseases. By specializing in immune metabolism, Istesso is dedicated to providing innovative solutions that enhance the diagnosis and treatment of serious health conditions, ultimately aiming to improve patient outcomes.

Featurespace

Venture Round in 2019
Featurespace is a technology company that develops Adaptive Behavioral Analytics and automated deep behavioral networks to prevent fraud and financial crime. Its ARIC platform provides real-time risk scoring and anomaly detection to monitor customer data across transactions and channels, automatically identifying risk, blocking new fraud attacks, and distinguishing genuine activity. The ARIC Risk Hub operates in real time and is used by more than 30 major global financial institutions to protect customers and revenue, spanning multiple countries. The company serves financial institutions and other sectors, including responsible gambling and churn protection, by analyzing streams of customer data to detect anomalies and prevent loss while minimizing disruption to legitimate customers.

AudioScenic

Seed Round in 2019
AudioScenic specializes in developing advanced 3D audio technology using small speaker arrays and head tracking. This enables immersive, personalized sound experiences without the need for headphones or multiple speakers, benefiting industries such as gaming, cinema, VR, and automotive.

import.io

Series B in 2018
Import.io Ltd, established in 2012, is a London-based Software as a Service (SaaS) company with an additional office in Los Gatos, California. It specializes in converting unstructured web data into structured, machine-readable formats. Import.io offers a suite of products, including automated web extraction, data monitoring, visualization, and analysis tools, as well as APIs for system integration. The company also provides solutions for competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 customers, delivering high-quality data from millions of web sources to fuel business insights and competitive advantage.

WaveOptics

Series C in 2018
WaveOptics, Ltd. is a designer and manufacturer of advanced augmented reality display technology, specializing in diffractive waveguides for wearable devices. Founded in 2014 and headquartered in Abingdon-on-Thames, United Kingdom, the company focuses on providing key optical components for augmented reality applications. WaveOptics employs patented technology that utilizes waveguide holography and photonic crystals to create lightweight, high-performance displays. Their innovative designs feature a high field of view and full RGB color, allowing for an enriched user experience without the bulk typically associated with traditional augmented reality systems. The company has established strategic partnerships with leading firms such as Compal, Wistron, and Plessey to enhance its product offerings and market reach.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.